CLL Featured Expert Videos: The Role of Biomarkers in Prognosis

The results of biomarker testing may be used to inform prognosis and treatment plans.

Diagnosis and Prognosis

CLL does not always present itself with obvious symptoms, so a blood test is used to diagnose CLL.1 Once diagnosed, a patient's prognosis may be informed by biomarker testing.

Biomarkers and Prognosis

Understanding genetic abnormalities in CLL is helpful in determining a patient's prognosis. Biomarkers are informative for prognosis and therapy determination. 

Recommended Evaluations

The guidelines set forth by NCCN, as well as those recently updated by iwCLL, offer recommendations for biomarker testing.

FISH Testing and Prognosis

NCCN and iwCLL both set recommendations for testing important biomarkers. Currently, fluorescent in situ hybridization (FISH) testing is used to detect genetic abnormalities in patients with CLL. This data helps HCPs determine patient prognosis and therapy selection.

Reference: 1. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.

Share this page

You are now leaving

By clicking "OK" below you will be taken to a website that may contain links or references to other websites to which our Privacy Policy may not apply. We encourage you to read the Privacy Policy of every website you visit.

For any questions about the Pharmacyclics Privacy Policy, please visit and click on the Privacy Policy link.